Literature DB >> 32264211

Encapsulation of Au/Fe3O4 nanoparticles into a polymer nanoarchitecture with combined near infrared-triggered chemo-photothermal therapy based on intracellular secondary protein understanding.

Ching-Wen Chen1, Wei-Jhe Syu, Tzu-Chi Huang, Yao-Chang Lee, Jong-Kai Hsiao, Kuo-Yi Huang, Hsiu-Ping Yu, Mei-Yi Liao, Ping-Shan Lai.   

Abstract

The combination of the functions of near infrared-triggered molecule release and chemo-photothermal therapy improved the therapeutic effect, but clarification of the cancer damage pathway in terms of protein molecule levels has yet to be well studied. In this study, we developed a polymer encapsulation synthesis of Au/Fe3O4@polymer nanoparticles as a Swiss army knife to integrate near infrared absorption, magnetism, and doxorubicin (DOX) loading ability into a single package. By exposing to near infrared absorption, the Au/Fe3O4@polymer nanoparticles possessed photothermal therapy, exhibiting anti-tumor growth suppression of HT-29 tumor-bearing nude mice with less body weight loss. To deeply understand the interactions between the drug-loaded nanocarriers and the protein structures of the treated cells, delivering therapeutic DOX agent combined with photothermal therapy with Au/Fe3O4@polymer nanostructures to cancer cells was investigated. Synchrotron-based FTIR imaging and confocal imaging showed direct observation of the efficient photo-chemotherapy impacting MCF7, MCF7/ADR, and HT-29 cells after the near infrared radiation-triggered DOX release. Our demonstration outlines how the cell destruction in the molecular mechanism was initiated by chemo-photothermal combination therapy after the translocation of DOX from the cytosol to the nuclei, leading to altered intracellular secondary proteins. For preclinical application of potential diagnosis to cancer cells, Au/Fe3O4@polymer nanoparticles performed integrated computed tomography/magnetic resonance imaging contrast enhancement and near infrared-triggered chemo-photothermal therapy.

Entities:  

Year:  2017        PMID: 32264211     DOI: 10.1039/c7tb00944e

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  7 in total

1.  Diagnostic and Therapeutic Nanomedicine.

Authors:  Jinmyoung Joo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.

Authors:  Sourav Bhattacharjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-02

3.  Au Catalyzing Control Release NO in vivo and Tumor Growth-Inhibiting Effect in Chemo-Photothermal Combination Therapy.

Authors:  Ying Zhang; Tianfu Zhou; Jian Li; Nuo Xu; Mingze Cai; Hong Zhang; Qinfu Zhao; Siling Wang
Journal:  Int J Nanomedicine       Date:  2021-03-29

4.  Mannoside-Modified Branched Gold Nanoparticles for Photothermal Therapy to MDA-MB-231 Cells.

Authors:  Han-Chen Lin; Keng-Fang Hsu; Chiao-Ling Lai; Tzu-Chien Wu; Hui-Fen Chen; Chian-Hui Lai
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

5.  Efficient uptake and retention of iron oxide-based nanoparticles in HeLa cells leads to an effective intracellular delivery of doxorubicin.

Authors:  R C Popescu; D Savu; I Dorobantu; B S Vasile; H Hosser; A Boldeiu; M Temelie; M Straticiuc; D A Iancu; E Andronescu; F Wenz; F A Giordano; C Herskind; M R Veldwijk
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

Review 6.  Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.

Authors:  Amreen Khan; Faith Dias; Suditi Neekhra; Barkha Singh; Rohit Srivastava
Journal:  Front Chem       Date:  2021-01-29       Impact factor: 5.221

7.  A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy.

Authors:  Pengcheng Xu; Ru Wang; Wenqian Yang; Yanyan Liu; Dongsheng He; Zixuan Ye; Daquan Chen; Yuan Ding; Jiasheng Tu; Yan Shen
Journal:  J Nanobiotechnology       Date:  2021-03-19       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.